Odyssey Therapeutics (ODTX) Q3 FY2026 earnings: revenue $0

Odyssey Therapeutics, Inc. (ODTX) reported revenue of $0 for Q3 FY2026, the quarter ended 30 September 2026. Net income was -$53 million, and diluted earnings per share $-1.10. The figures are the company's own, from the 10-Q it filed with the SEC on 4 November 2026.

Revenue

Q1 FY2025Q3 FY2026

Operating margin

n/a

-38640.4% a year earlier

Q1 FY2025Q3 FY2026

Net income

-$53 million

Q1 FY2025Q3 FY2026

Diluted EPS

-$1.10

Q1 FY2025Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 1 new, 3 kept.

Additional OD-001 induction analyses presented: In October the company presented further Phase 2a induction findings at UEG Week, based on 56 efficacy-evaluable patients with moderate-to-severe ulcerative colitis, with new clinical and translational analyses shared in a webcast.
Efficacy backed by biomarkers and transcriptomics: Management said the clinical efficacy results are supported by concordant findings in clinical outcomes, inflammatory biomarkers, mucosal transcriptomics and histologic improvement, consistent with RIPK2 scaffolding inhibition.
OD-002 IND-enabling studies completed: The company completed IND-enabling studies for OD-002, an oral SLC15A4 inhibitor, which the prior release had planned for the second half of 2026.

Read the earnings call summary

Income statement (profit and loss)

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Revenue	0.0	0.0	0.1
Research and development	42.1	36.2	26.3	+16.3%	+60.0%
Operating income	-56.7	-55.5	-38.3
Operating margin	n/a	n/a	-38640.4%
Interest expense	0.0	0.0	0.0	-40.0%	+1,100.0%
Pre-tax income	-53.0	-52.8	-35.5
Income tax	0.0	-0.0	-0.1
Net income	-53.1	-52.8	-35.5
Net margin	n/a	n/a	-35820.2%
Diluted EPS	-$1.10	-$1.74	-$7.78

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Operating cash flow	-41.5	-34.5	-31.3
Capital expenditure	0.5	0.2	0.0	+171.0%	+950.0%
Free cash flow	-42.0	-34.7	-31.3
Free cash flow margin	n/a	n/a	-31621.2%
Cash from investing	43.3	-211	-173
Cash from financing	-3.2	292	90.8
Depreciation and amortisation	1.0	1.0	1.2	-3.3%	-15.1%
Share-based compensation	7.9	5.7	4.9	+40.0%	+62.2%
Diluted shares, weighted	48m	30m	5m	+58.6%	+953.6%
Shares outstanding at period end	48m	48m	48m	+0.1%	-0.3%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Shareholders' equity	376	421	-461	-10.8%
Debt	0.0	0.0	n/a
Operating lease liabilities	17.9	19.4	n/a	-7.3%
Other liabilities	44.4	43.3	n/a	+2.6%
Total liabilities and equity	438	484	n/a	-9.5%
Fixed assets	4.6	4.9	n/a	-5.1%
Goodwill	14.1	14.1	n/a	+0.1%
Intangible assets	0.0	0.1	n/a
Investments	306	351	n/a	-12.7%
Cash and equivalents	80.6	82.0	49.5	-1.7%	+62.8%
Receivables	0.0	0.0	0.0
Other assets	32.4	31.7	n/a	+2.0%
Total assets	438	484	n/a	-9.5%

Questions

What was Odyssey Therapeutics' revenue in Q3 FY2026?

Odyssey Therapeutics (ODTX) reported revenue of $0 for Q3 FY2026, the quarter ended 30 September 2026.

How much did Odyssey Therapeutics earn in Q3 FY2026?

Net loss for Q3 FY2026 was $53 million, and the diluted loss per share $1.10.

When did Odyssey Therapeutics report Q3 FY2026 results?

Odyssey Therapeutics filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 4 November 2026.

Quarterly results, the last 6 quarters

	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	1.9	1.0	0.1	0.0	0.0	0.0
R&D	38.8	30.2	26.3	32.3	36.2	42.1
Operating income	-39.2	-41.9	-38.3	-39.8	-55.5	-56.7
Operating margin	-2042%	-4371%	-38640%	n/a	n/a	n/a
Interest expense	0.0	0.0	0.0	0.0	0.0	0.0
Pre-tax income	-38.3	-41.2	-35.5	-38.2	-52.8	-53.0
Net income	-38.4	-41.2	-35.5	-38.3	-52.8	-53.1
Net margin	-2004%	-4300%	-35820%	n/a	n/a	n/a
Diluted EPS	-$39.37	-$29.54	-$7.78	-$6.77	-$1.74	-$1.10
Operating cash flow	-38.6	-34.3	-31.3	-41.0	-34.5	-41.5
Capital expenditure	0.9	0.0	0.0	0.1	0.2	0.5
Free cash flow	-39.5	-34.3	-31.3	-41.2	-34.7	-42.0
Shares outstanding	48m	48m	48m	2m	48m	48m
Filing	10-Q	10-Q	10-Q	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 4 November 2026: the filing.